Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Penile Neoplasms 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1

Interventions

pembrolizumab 6Nivolumab 3budigalimab 2Paclitaxel 2Ipilimumab 2Docetaxel 2venetoclax 1tislelizumab 1talazoparib 1spartalizumab 1rovalpituzumab tesirine 1regorafenib 1obinutuzumab 1naptumomab estafenatox 1fludarabine 1epacadostat 1durvalumab 1cabozantinib 1Platinum 1Levoleucovorin 1Leucovorin 1Interleukin-2 1IPI-549 1Gemcitabine 1Fluorodeoxyglucose F18 1Everolimus 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × BAY 1895344 × Other solid neoplasm × Clear all
NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡